# Antibiotic Stewardship in Canine Skin Infections: Choosing Wisely


## Key Takeaways

- **Cytology is the cornerstone of antibiotic stewardship for canine skin infections:** Systemic antibiotics should only be prescribed after cytology confirms bacterial infection (presence of degenerate neutrophils with intracellular bacteria) and identifies bacterial morphology (cocci vs. rods), thereby avoiding unnecessary exposure for cases of overgrowth or non-infectious dermatoses.
- **Distinguish infection depth and bacterial morphology to guide therapy:** Surface pyodermas often respond to topical antimicrobials (e.g., chlorhexidine), while deep pyodermas necessitate systemic antibiotics; the presence of rods on cytology mandates culture and susceptibility testing due to potential Gram-negative or anaerobic involvement.
- **Empirical antibiotic selection should prioritize narrow-spectrum agents:** For first-episode superficial pyoderma with cocci and no prior antibiotic exposure, first-generation cephalosporins or potentiated amoxicillin are recommended to target *Staphylococcus pseudintermedius* and preserve broader-spectrum agents for resistant or complex cases.
- **Culture and susceptibility testing are indicated for specific scenarios:** Culture is warranted for rod-shaped bacteria on cytology, deep infections, recurrent pyoderma, prior antibiotic failure, or suspected multidrug-resistant organisms (e.g., MRSP) to guide appropriate drug selection and avoid empirical use of last-resort antibiotics.
- **Therapy duration is critical and extends beyond clinical resolution:** Antibiotic courses should continue for at least 7 days beyond clinical resolution, with rechecks to confirm clearance, rather than dispensing fixed durations, to prevent relapse and mitigate resistance development.
- **Topical therapy is the default for superficial pyoderma:** Chlorhexidine-based shampoos and sprays are highly effective for localized or generalized superficial pyodermas, significantly reducing the need for systemic antibiotics and aligning with global efforts to preserve antibiotic efficacy.

---

Canine skin infections are among the most common reasons for veterinary consultation, and they account for a substantial proportion of systemic antibiotic prescriptions in small animal practice. Many of these prescriptions are unnecessary, inappropriate in spectrum, or continued beyond the point of clinical resolution. This article provides a diagnostic reasoning framework for the practising veterinarian, working through the decision pathway from lesion classification and cytology to culture indications, drug selection, and therapy monitoring. The goal is to preserve antibiotic efficacy for the cases that genuinely require it while avoiding the harms of unnecessary exposure, both for the individual patient and for the broader bacterial population.

The clinical question this article answers is direct: when a dog presents with a skin lesion, how does the clinician decide whether antibiotics are indicated, which antibiotic to choose, and when to stop? The answer rests on distinguishing infection from other inflammatory dermatoses, identifying the bacterial population and its resistance profile when treatment is warranted, and selecting a drug with the narrowest effective spectrum for the shortest justified duration. The principles align with the [professional stewardship guidance of the AVMA](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance), which frames judicious antimicrobial use as a core professional obligation instead of an optional refinement.

## At a Glance

| Parameter | Clinical Decision Point |
|---|---|
| Primary lesion classification | Identify pustules, papules, epidermal collarettes, or furuncles before considering infection |
| Cytology | Collect from intact pustules or under the edge of crusts, assess for bacteria and inflammatory cells |
| Bacterial morphology | Cocci versus rods directs initial drug selection and raises suspicion for Gram-negative involvement |
| Surface versus deep infection | Surface pyodermas often respond to topical therapy alone, deep infections require systemic antibiotics |
| Culture indication | Rods on cytology, prior antibiotic failure, recurrent pyoderma, or suspected multidrug resistance |
| First-line drug selection | Narrow-spectrum agents active against Staphylococcus pseudintermedius, avoid fluoroquinolones empirically |
| Therapy duration | Treat 7 days beyond clinical resolution, recheck instead of dispense fixed courses |
| Stewardship trigger | Recurrent or nonresponsive cases warrant diagnostic investigation, not antibiotic rotation |

## The Resistance Imperative

Antibiotic resistance is no longer a hospital phenomenon confined to human medicine. Resistant strains now circulate widely in the community, in animals, and in the environment, driven by excessive and inappropriate antibiotic use across human health, livestock production, and aquaculture. The [review of multidrug-resistant bacteria and alternative control methods](https://pubmed.ncbi.nlm.nih.gov/30811275/) identifies the excessive use of broad-spectrum agents and the absence of robust stewardship programs as primary drivers of this spread. The consequence is a shrinking pool of reliable therapeutic options, with projections that few effective antibiotics will remain available if current trends continue.

Veterinary dermatology sits squarely within this problem. Staphylococcus pseudintermedius, the principal bacterial pathogen of canine skin, has demonstrated a capacity to acquire resistance to every antibiotic class deployed against it. Methicillin-resistant S. pseudintermedius (MRSP) infections are now encountered in general practice, also referral settings. Each unnecessary prescription selects for resistance in the individual patient's commensal flora and contributes to the environmental reservoir. The [global analysis of antibiotic use in agriculture and its environmental consequences](https://pubmed.ncbi.nlm.nih.gov/29601469/) documents how resistant organizms move through food chains and animal wastes into the wider ecosystem, with no geographic boundaries impeding their spread.

## Why Skin Infections Invite Overuse

Several features of canine pyoderma make it particularly susceptible to antibiotic overuse. The clinical signs, erythema, alopecia, scaling, and pruritus, overlap extensively with noninfectious dermatoses such as allergic dermatitis, endocrinopathy, and keratinisation disorders. Secondary bacterial overgrowth on a diseased skin barrier is common, but overgrowth is not equivalent to infection requiring systemic therapy. The distinction between colonisation, overgrowth, and true infection is frequently blurred in clinical decision making.

A second driver is diagnostic momentum. When a dog presents with pruritus and erythema, the temptation is to prescribe an antibiotic alongside the anti-inflammatory treatment to cover the possibility of infection. This reflexive prescribing ignores the cytological evidence that should guide the decision. A third driver is client expectation. Owners often equate visible skin disease with a need for antibiotics, and the time pressure of a consultation can push clinicians toward a prescription instead of a diagnostic procedure. None of these pressures justifies deviating from the [judicious use principles articulated by the AVMA](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance), which require that antimicrobials be used only when a bacterial infection is confirmed or strongly suspected on clinical and cytological grounds.

## The Diagnostic Hierarchy

The diagnostic approach to canine skin disease follows a defined hierarchy. The first step is lesion identification. True bacterial infection produces pustules, papules, epidermal collarettes, or furuncles. Macular erythema, scaling, and alopecia without these primary lesions do not constitute evidence of infection. The second step is cytological confirmation. Impression smears from intact pustules, or from the underside of freshly lifted crusts, should demonstrate bacteria in association with inflammatory cells. The presence of degenerate neutrophils with intracellular bacteria is the cytological hallmark of active infection.

The third step is bacterial morphology assessment. Cocci in pairs, tetrads, or clusters are consistent with staphylococcal infection and guide initial therapy toward agents with activity against S. pseudintermedius. Rods on cytology indicate Gram-negative organizms, most commonly Pseudomonas aeruginosa or Escherichia coli, and change both the drug selection and the likelihood that culture will be required. The fourth step is depth assessment. Surface pyodermas, including impetigo and superficial bacterial folliculitis, often respond to topical antimicrobial therapy alone. Deep pyodermas, with furunculosis, cellulitis, or draining tracts, require systemic antibiotics and a more extended treatment course.

## Classification Systems and Their Limits

The [MSD Veterinary Manual](https://www.msdvetmanual.com/) provides the standard classification of canine pyoderma by depth and aetiology, distinguishing surface, superficial, and deep forms. This classification is clinically useful because it predicts both therapeutic approach and expected duration. Surface infections may resolve with topical chlorhexidine or benzoyl peroxide products. Superficial infections typically require systemic antibiotics when lesions are generalized, though localized disease may still respond to topical therapy. Deep infections always require systemic antibiotics, often for six to twelve weeks, and warrant culture before therapy is initiated.

The classification has limits. It does not capture the distinction between primary infection and secondary overgrowth on an allergic or endocrinopathic skin barrier. It also does not address the resistance profile of the infecting organizm, which is a separate axis of decision making. The clinician must therefore hold two frameworks simultaneously: the depth-based classification that determines whether systemic therapy is needed, and the resistance-based framework that determines which antibiotic is appropriate. The [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/) emphasize surveillance and prudent use as international obligations, reinforcing that individual prescribing decisions aggregate into population-level resistance patterns.

## The Stewardship Mindset

Stewardship in dermatology is not a fixed protocol but a recurring clinical habit. It begins with asking whether antibiotics are indicated at all, proceeds to selecting the narrowest effective agent when they are, and ends with defining a stopping criterion before the first dose is dispensed. The [FDA Center for Veterinary Medicine](https://www.fda.gov/animal-veterinary) provides regulatory context for approved drug use and extralabel prescribing, but the clinical judgment of indication and duration rests with the practitioner. Each antibiotic prescription should be justified in the medical record by cytological findings, a stated clinical diagnosis, and a planned recheck interval. This documentation discipline is the practical expression of stewardship in daily practice.

## The Cytology-First Decision Sequence

The single most useful habit in antibiotic stewardship for canine skin infections is to treat cytology as a gatekeeper. No antibiotic should be prescribed for a skin lesion until cytology has confirmed a bacterial infection and indicated its character. This rule applies to every lesion type, including those that appear obviously infected on gross inspection.

The sequence is straightforward. Collect samples before any topical or systemic therapy begins. Use impression smears for exudative lesions, acetate tape preparations for intact pustules and papules, and swabs for deep draining tracts. Stain with Diff-Quik or equivalent. Read the smear systematically for three features: the presence and morphology of bacteria, the ratio of degenerate to non-degenerate neutrophils, and the presence or absence of cocci versus rods.

Interpretation drives the decision. Degenerate neutrophils with intracellular bacteria confirm true infection instead of surface colonisation. Extracellular bacteria alone, particularly in a smear with healthy neutrophils, suggest contamination or colonisation and do not justify systemic antibiotics. Cocci in pairs or clusters point toward staphylococci, while rods indicate Gram-negative organizms or anaerobes and change both the drug choice and the diagnostic plan.

The cytology result also determines whether topical therapy can replace systemic therapy. Superficial pyoderma with cocci and intact pustules often responds to topical chlorhexidine alone. Deep pyoderma, furunculosis, or lesions with rods require systemic therapy and usually culture. This cytology-first approach directly reduces unnecessary systemic antibiotic exposure in the large population of dogs with surface pyoderma or bacterial overgrowth that never requires systemic drugs.

## When to Culture and When to Trust Empiricism

Cytology narrows the differential but does not identify the species or the resistance profile. Culture is indicated when any of the following conditions apply: rods are seen on cytology, the lesion is deep or recurrent, the dog has received antibiotics within the previous 30 days, or the infection fails to respond to an appropriate first-line agent within the expected interval.

Empirical therapy is acceptable for first-episode superficial pyoderma with cocci on cytology in a dog with no recent antibiotic history. The expected pathogen is Staphylococcus pseudintermedius, and the expected susceptibility profile favours first-line agents. This is the one clinical scenario where empirical treatment is defensible, and even here the drug should be chosen from the narrowest effective class.

Culture results must be interpreted with the cytology in mind. A culture growing coagulase-negative staphylococci or environmental contaminants from a swab of an open lesion does not represent the infecting organizm. Deep tissue biopsy for culture is the reference standard for deep pyoderma and should be pursued when superficial swabs yield ambiguous results. Susceptibility testing should be requested with the understanding that breakpoints are derived from human pharmacokinetic-pharmacodynamic data and may not perfectly predict canine clinical response, but they remain the best available guide.

## First-Line and Alternative Antibiotic Selection

The table below presents a stewardship-oriented selection framework. The choices reflect the expected susceptibility of canine staphylococci and the need to preserve drugs of last resort. Current formulary and label references must be consulted for doses, durations, and species-specific contraindications before prescribing.

| Clinical Scenario | First-Line Choice | Alternative | Rationale for Stewardship |
|---|---|---|---|
| Superficial pyoderma, cocci, no prior antibiotics | First-generation cephalosporin or potentiated amoxicillin | Clindamycin | Narrow spectrum, good staphylococcal activity, low collateral damage |
| Superficial pyoderma, recurrent or prior antibiotic exposure | Culture-guided therapy | Consider clindamycin if susceptibility confirmed | Avoids blind repetition of prior drugs |
| Deep pyoderma, cocci on cytology | Culture-guided therapy with first-generation cephalosporin while awaiting results | Potentiated amoxicillin if susceptibility supports | Deep infections warrant culture, empiric choice should be narrowest plausible |
| Rods on cytology, any depth | Culture and susceptibility before therapy | Temporary topical chlorhexidine while awaiting culture | Rods imply Gram-negative or anaerobic flora, blind therapy risks failure and resistance |
| Suspected MRSP or multidrug-resistant infection | Culture and susceptibility mandatory | Consider chlorhexidine-based topical therapy as adjunct | Resistance in staphylococci limits oral options, stewardship requires confirmation before using reserve drugs |

The pattern is consistent. First-generation cephalosporins and potentiated amoxicillin remain the workhorses for canine staphylococcal pyoderma. Fluoroquinolones, third-generation cephalosporins, and amoxicillin-clavulanate combinations should be reserved for culture-confirmed infections that fail first-line therapy. The emergence of multidrug-resistant organizms across human and animal health, documented in the review of [multidrug-resistant bacteria and alternative control methods](https://pubmed.ncbi.nlm.nih.gov/30811275/), makes this hierarchy a professional obligation instead of a preference.

## Monitoring Response and Defining Failure

Every antibiotic prescription for canine skin infection requires a defined monitoring plan. The owner should be told what improvement looks like, when it should appear, and what to do if it does not. The veterinarian should record the expected response interval in the medical record at the time of prescribing.

For superficial pyoderma, pruritus and lesion count should begin to improve within 7 to 14 days of appropriate therapy. Deep pyoderma requires longer, often 3 to 4 weeks before visible improvement, and complete resolution may take 8 to 12 weeks. Failure to improve within these windows is an indication for re-evaluation, not for changing drugs blindly.

Re-evaluation should include repeat cytology, assessment of owner compliance, and review of the original culture and susceptibility results. A common failure mode is treating a secondary bacterial infection while the primary disease, such as atopic dermatitis, endocrinopathy, or demodicosis, remains uncontrolled. Antibiotic therapy will not resolve pyoderma that is continuously re-seeded by an untreated primary process. The stewardship failure here is not the antibiotic choice but the failure to identify and manage the underlying disease.

Documentation should capture the cytology findings, the drug selected, the dose and duration, the expected response date, and the plan if response is inadequate. This record supports continuity of care and prevents the common error of restarting the same antibiotic months later without reassessing whether the indication still exists.

## Topical Therapy as the Stewardship Default

Topical therapy deserves emphasis as the first-line intervention for most superficial bacterial skin infections. Chlorhexidine shampoos, sprays, and wipes at appropriate concentrations are effective against staphylococci and reduce the need for systemic antibiotics. Mupirocin and fusidic acid preparations are useful for localized lesions, though their use should be reserved for small areas to limit the development of resistance to these valuable topical agents.

The decision between topical and systemic therapy rests on lesion extent and depth. Localized superficial pyoderma with intact pustules can be managed topically. Generalized superficial pyoderma, deep pyoderma, or infections in immunocompromised patients require systemic therapy. Topical therapy should continue alongside systemic therapy in deep infections to reduce bacterial load and speed resolution.

The global pressure to preserve antibiotic efficacy, including the recognition that [vaccines can reduce antimicrobial resistance by preventing infections](https://pubmed.ncbi.nlm.nih.gov/31622674/), reinforces the logic of using non-antibiotic and topical modalities wherever they can achieve the clinical goal. For canine skin infections, topical chlorhexidine is the most reliable of these modalities and should be the default recommendation whenever the lesion distribution permits it.

## Recognized Complications and Early Detection

The most consequential failure mode in treating canine pyoderma is the progression from superficial to deep infection while the patient appears to be on appropriate therapy. Deep pyoderma may present with furuncles, draining tracts, or hemorrhagic bullae, but early deep infection can be subtle, with only mild erythema and focal crusting that mimics superficial disease. Serial cytology is the discriminating tool. Impression smears from intact pustules or the underside of lifted crusts that show neutrophils with intracellular bacteria confirm active infection, whereas smears dominated by acantholytic keratinocytes without bacteria suggest an immune-mediated process and should halt antibiotic escalation.

A second failure mode is the selection of a drug that is active in vitro but ineffective in vivo because of poor cutaneous penetration or protein binding. This is most often seen with drugs chosen for convenience instead of for skin-specific pharmacokinetics. The corrective action is to consult the [MSD Veterinary Manual](https://www.msdvetmanual.com/) for drug-specific skin penetration data and to prefer agents with documented efficacy in canine pyoderma.

Treatment duration errors are common. Stopping at clinical resolution, instead of continuing for a defined period beyond resolution, invites relapse and promotes resistance. Conversely, extending therapy without cytological confirmation of clearance prolongs unnecessary antibiotic exposure. The [AVMA antimicrobial stewardship resources](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance) emphasize that duration should be tied to documented response, not to a fixed calendar date.

## Common Errors and Corrective Actions

Less experienced clinicians frequently mistake surface bacterial overgrowth for true infection. Surface overgrowth responds to topical therapy alone, and systemic antibiotics are unnecessary. The corrective action is to distinguish surface from superficial infection by lesion morphology and cytology before prescribing.

A second recurring error is culturing every recurrent pyoderma without first optimizing topical therapy and managing the underlying allergic or endocrine disease. Culture results from a surface-contaminated sample are misleading and may prompt escalation to drugs that are unnecessary. Culture is indicated when cytology confirms infection, when rod-shaped bacteria are seen, or when the patient has failed an appropriate first-line course.

A third error is treating the cytology result instead of the whole patient. A finding of Malassezia organizms on cytology does not justify systemic antifungals unless clinical lesions and pruritus correlate. The same principle applies to low numbers of cocci on a smear from a dog with no active pustules.

## Limitations of the Evidence and Divergent Expert Opinion

The evidence base for antibiotic selection in canine pyoderma rests largely on clinical experience, pharmacokinetic studies, and susceptibility data instead of on large randomised controlled trials. Expert opinion diverges on several points. One is the threshold for performing culture and susceptibility testing in recurrent pyoderma. Some authorities recommend culture after a single failed course, while others reserve culture for cases with rods, deep infection, or prior multidrug-resistant isolates. Another point of divergence is the role of fluoroquinolones as first-line therapy. Their excellent skin penetration is offset by resistance concerns, and many stewardship programs now position them as second-line agents. The [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/) and the [FDA Center for Veterinary Medicine](https://www.fda.gov/animal-veterinary) both support restricting use of drugs that are critical for human medicine, but the practical implementation in companion animal practice varies by region and by practice setting.

## Referral, Consultation, and Reporting

Referral to a veterinary dermatologist is warranted when a dog has failed two appropriately selected and dosed antibiotic courses with cytological confirmation of infection, when multidrug-resistant organizms are isolated, or when the differential diagnosis includes immune-mediated skin disease that mimics infection. Dermatopathology and specialised diagnostic testing are often needed in these cases.

Laboratory involvement is indicated for culture and susceptibility testing, for histopathology when neoplasia or autoimmune disease is suspected, and for endocrine testing when an underlying cause of recurrent pyoderma is sought. The laboratory should be consulted before sampling to confirm appropriate transport media and handling for the suspected organizm.

Regulatory reporting obligations vary by jurisdiction. Veterinarians should be aware of local requirements for reporting notifiable diseases and for documenting extralabel drug use. The [AVMA practice resources](https://www.avma.org/resources-tools) provide guidance on record keeping and on the responsible use of antimicrobials within the legal framework of the practice location.

## Troubleshooting Table

| Observation | Likely Cause | Discriminating Check |
|---|---|---|
| Pustules persist after 7 days of first-line therapy | Wrong drug, resistant organizm, or non-infectious mimic | Repeat cytology, culture if rods or intracellular bacteria persist |
| Clinical improvement but cytology still shows bacteria | Inadequate duration or dose | Continue therapy, recheck cytology in 7 days before extending |
| Pruritus worsens during therapy | Underlying allergy unmasked, or drug reaction | Assess lesion distribution, consider antihistamine or glucocorticoid only after excluding drug eruption |
| Draining tracts develop during therapy | Deep pyoderma or furunculosis | Cytology from tract exudate, consider histopathology |
| Culture grows multiple organizms | Surface contamination or mixed infection | Compare culture results with cytology, repeat sampling from intact lesions |
| Recurrence within weeks of stopping therapy | Underlying endocrine or allergic disease untreated | Endocrine testing, dermatology referral for allergy workup |

## Frequently Asked Questions

### How Do I Manage a Suspected Pyoderma When Cytology Is Not Available?

Cytology is the single most informative test for guiding antibiotic decisions, but it is not always available. When it is not, base the decision on lesion morphology and the clinical pattern. If the lesions are consistent with superficial pyoderma, such as papules, pustules, or epidermal collarettes, and the dog has no systemic signs, topical therapy alone is a reasonable first step. This approach aligns with the stewardship principle of reserving systemic antibiotics for cases where they are clearly indicated. If lesions are deep, such as furuncles, ulcers, or draining tracts, systemic antibiotics are justified even without cytology, but a culture should be collected before starting therapy. Document the absence of cytology in the record and revisit the diagnosis if response is poor.

### What Should I Do When Cost Prevents the Owner from Filling the Antibiotic Prescription?

Cost is a real barrier to stewardship because an owner who cannot afford the first-line drug may pressure you to prescribe a cheaper, broader-spectrum agent. Resist that pressure. First-line drugs such as first-generation cephalosporins are generally inexpensive, so cost rarely justifies a switch to a fluoroquinolone or a third-generation cephalosporin. If the owner cannot afford any systemic antibiotic, topical therapy becomes the primary treatment. Chlorhexidine-based products are cost-effective and can resolve many superficial infections without systemic drugs. For deep infections where topical therapy is inadequate, discuss payment options or referral to a lower-cost clinic. Prescribing a broad-spectrum drug to accommodate cost undermines the diagnostic reasoning that selected the first-line agent and contributes to the resistance pressure described in reviews of [antibiotic resistance as a public health challenge](https://pubmed.ncbi.nlm.nih.gov/30811275/).

### How Do I Adjust My Approach for a Dog with Suspected Methicillin-Resistant Staphylococcal Pyoderma?

Suspect methicillin-resistant Staphylococcus pseudintermedius (MRSP) when a confirmed bacterial pyoderma fails to respond to an appropriate first-line antibiotic, when cytology shows persistent cocci despite treatment, or when the dog has recent antibiotic exposure. Do not switch empirically to a fluoroquinolone. Collect a sample for culture and susceptibility testing before any further systemic therapy. While awaiting results, intensify topical therapy with chlorhexidine or benzoyl peroxide. If the infection is superficial, topical therapy alone may resolve it, and systemic antibiotics may not be needed at all. If systemic therapy is required, choose a drug based on the susceptibility report, not on a formulary default. The emergence of multidrug-resistant organizms in veterinary patients mirrors the broader trend of [resistance spreading through excessive and inappropriate antibiotic use](https://pubmed.ncbi.nlm.nih.gov/30811275/), so each MRSP case should trigger a review of your practice's prescribing habits.

### What Records Should I Keep to Support Stewardship Decisions?

The medical record should document the indication for antibiotics, the drug selected, the dose, the expected duration, and the planned recheck date. Record the cytology findings, including the presence of bacteria and inflammatory cells, and note whether a culture was submitted. If antibiotics are withheld, write the rationale, such as "superficial pyoderma, topical therapy elected." If a client declines a recommended test or treatment, record that conversation. These records serve two purposes. They support continuity of care if another clinician sees the dog, and they provide a defensible basis for prescribing decisions if the case is reviewed. Professional guidance on [judicious antimicrobial use and stewardship principles](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance) emphasizes that stewardship is a documented clinical process, not an abstract ideal.

### How Do I Explain to an Owner Why Their Dog Does Not Need Antibiotics?

Owners often expect antibiotics because they associate infection with a prescription. Explain that the dog has a bacterial infection on the skin, but that topical therapy can treat it without systemic drugs. Use the analogy of a skin wound: cleaning and disinfecting the surface is often enough, and oral antibiotics are reserved for infections that are deep, spreading, or not responding to surface treatment. Acknowledge that this approach may take longer and requires consistent application of the topical product. If the owner remains anxious, schedule a short recheck in 7 to 10 days to document progress. This conversation is a form of stewardship because it prevents unnecessary systemic exposure. The global drivers of resistance include [over-prescribing and misuse of antibiotics](https://pubmed.ncbi.nlm.nih.gov/31622674/), and client education is one practical way to counter that trend in daily practice.

### When Should I Consider Referral for a Dog with Recurrent Pyoderma?

Referral is appropriate when a dog has had three or more episodes of pyoderma in 12 months, when a confirmed infection fails to respond to two appropriately selected antibiotics, or when the diagnostic workup for an underlying cause is beyond your practice's resources. Recurrent pyoderma is almost always a signal of an underlying condition, such as atopic dermatitis, endocrinopathy, or a keratinisation defect, and treating the infection without addressing the cause guarantees recurrence. Referral is also warranted when MRSP is confirmed and you do not have access to the drugs listed on the susceptibility report. Before referring, ensure the owner understands that the referral is for diagnosis of the underlying disease, also for another antibiotic. The [MSD Veterinary Manual](https://www.msdvetmanual.com/) provides background on the range of conditions that predispose dogs to recurrent skin infections, which can help frame the discussion with the owner.

## Related Clinical & Scientific Guides

* [Veterinary Formulary Essentials: Navigating Drug References](/knowledge/veterinary-medicine/clinical-pharmacology/veterinary-formulary-essentials-navigating-drug-references)
* [Drug Interactions with Antiepileptic Drugs in Veterinary Patients: Managing Polypharmacy](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-antiepileptic-veterinary)
* [Drug Interactions with Corticosteroids in Veterinary Patients: A Comprehensive Review](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-corticosteroids-veterinary-comprehensive)


## References and Further Reading

- [Multidrug-Resistant Bacteria and Alternative Methods to Control Them: An Overview.](https://pubmed.ncbi.nlm.nih.gov/30811275/). 2019.
- [Impact of vaccines on antimicrobial resistance.](https://pubmed.ncbi.nlm.nih.gov/31622674/). 2020.
- [Adverse consequences of neonatal antibiotic exposure.](https://pubmed.ncbi.nlm.nih.gov/26886785/). 2016.
- [How should we respond to the emergence of plasmid-mediated colistin resistance in humans and animals?](https://pubmed.ncbi.nlm.nih.gov/27915108/). 2017.
- [The One Health stewardship of colistin as an antibiotic of last resort for human health in South Africa.](https://pubmed.ncbi.nlm.nih.gov/29673734/). 2018.
- [Antibiotic Use in Agriculture and Its Consequential Resistance in Environmental Sources: Potential Public Health Implications.](https://pubmed.ncbi.nlm.nih.gov/29601469/). 2018.
- [FDA Center for Veterinary Medicine: Animal Drug Information](https://www.fda.gov/animal-veterinary). FDA CVM.
- [AVMA Antimicrobial Use and Stewardship](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance). American Veterinary Medical Association.
- [MSD Veterinary Manual, Professional Edition](https://www.msdvetmanual.com/). MSD Veterinary Manual.

## Related Articles

- [Antimicrobial Stewardship in Canine Diarrhea: When Antibiotics Are Not the Answer](/knowledge/veterinary-medicine/clinical-pharmacology/antimicrobial-stewardship-canine-diarrhea)
- [Antimicrobial Stewardship in Canine Periodontal Disease: Antibiotic Use in Dentistry](/knowledge/veterinary-medicine/clinical-pharmacology/antimicrobial-stewardship-canine-periodontal)
- [Antimicrobial Stewardship in Canine Postoperative Infections: Prevention and Treatment](/knowledge/veterinary-medicine/clinical-pharmacology/antimicrobial-stewardship-canine-postoperative)
- [Antimicrobial Stewardship in Respiratory Infections of Dogs and Cats](/knowledge/veterinary-medicine/clinical-pharmacology/antimicrobial-stewardship-respiratory-infections-dogs-cats)
- [Antimicrobial Stewardship in Feline Respiratory Infections: When Antibiotics Are Needed](/knowledge/veterinary-medicine/clinical-pharmacology/antimicrobial-stewardship-feline-respiratory)

> This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.